整合基因的拷贝数与表达信息识别胶质瘤风险通路区域内的生存标志物

doi:10.3969/j.issn.1004-616x.2017.01.005

Abstract

Abstract:

OBJECTIVE: To identify the relationship among gene copy number and their expression with survival of glioma. METHODS: Based on the gene copy number variation data and mRNA expression information of 95 glioma patients,we organized a new expression profile. Samples were divided into two groups by the copy number variation and by using t test differential genes. The data were annotated into 300 pathways from KEGG pathway database. Applying with the Subpathway-GM method,we identified risky subpathways. Kaplan-Meier method and Log-rank test were used to predict genes which were highly related to the survival of glioma. RESULTS: 2 219 differential genes were obtained by using t test,as well as 48 risky subpathways by Subpathway-GM method. Studying the relathion between the 14 genes precticted by using survival method and the top 10 risky subpathways,we found that MDH2,YWHAE,SHB2B, CACNG4 and CACNA1G could be regard as survival markers of glioma. CONCLUSION: By combining glioma patients' copy number variation of gene,their expression information and the topological structure of the pathways,we identified some survival markers for the diagnosis and treatment of glioma.

Key words: glioma, copy number variation, Subpathway-GM method, subpathways, markers

CLC Number:

R318.04

PAN Qi, LI Meng, QIAN Fengcui, TANG Zhidong, ZHAO Yue, WANG Qiuyu, LI Chunquan. Copy number of gene and their expression as survival markers for glioma[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(1): 23-30,36.

References

[1] OMURO A,DEANGELIS L M. Glioblastoma and other malignant gliomas:a clinical review[J]. JAMA,2013,310(17):1842-1850.

[2] DEORAH S,LYNCH C F,SIBENALLER Z A,et al. Trends in brain cancer incidence and survival in the United States:surveillance,epidemiology,and end results program,1973 to 2001[J]. Neurosurg Focus,2006,20(4):E1.

[3] FURNARI F B,FENTON T,BACHOO R M,et al. Malignant astrocytic glioma:genetics,biology,and paths to treatment[J]. Genes Dev,2007,21(21):2683-2710.

[4] OHGAKI H,DESSEN P,JOURDE B,et al. Genetic pathways to glioblastoma:a population-based study[J]. Cancer Res,2004, 64(19):6892-6899.

[5] BEROUKHIM R,MERMEL C H,PORTER D,et al. The landscape of somatic copy-number alteration across human cancers[J]. Nature, 2010,463(7283):899-905.

[6] YOSHIHARA K,TAJIMA A,ADACHI S,et al. Germline copy number variations in BRCA1-associated ovarian cancer patients[J]. Genes Chrom Cancer,2011,50(3):167-177.

[7] LI C,HAN J,YAO Q,et al. Subpathway-GM:identification of metabolic subpathways via joint power of interesting genes and metabolites and their topologies within pathways[J]. Nucleic Acids Res,2013,41(9):e101.

[8] MERMEL C H,SCHUMACHER S E,HILL B,et al. GISTIC 2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers[J]. Genome Biol,2011,12(4):R41.

[9] LI C,LI X,MIAO Y,et al. Subpathway miner:a software package for flexible identification of pathways[J]. Nucleic Acids Res,2009,37(19):e131.

[10] PAN H C,JIANG Q,Y U Y,et al. Quercetin promotes cell apoptosis and inhibits the expression of MMP-9 and fibronectin via the AKT and ERK signalling pathways in human glioma cells[J]. Neurochem Int,2015,80:60-71.

[11] WANG G P,HAN X F. CD9 modulates proliferation of human glioblastoma cells via epidermal growth factor receptor signaling[J]. Mol Med Rep,2015,12(1):1381-1386.

[12] ZHAO L. Hirudin inhibits cell growth via ERK/MAPK signaling in human glioma[J]. Int J Clin Exp Med,2015,8(11):20983-20987.

[13] YANG N,WANG Y,HUI L,et al. Silencing SOX2 expression by RNA interference inhibits proliferation,invasion and metastasis,and induces apoptosis through MAP4K4/JNK signaling pathway in human laryngeal cancer TU212 cells[J]. J Histochem Cytochem,2015,63(9):721-733.

[14] HALATSCH M E,LOW S,MURSCH K,et al. Candidate genes for sensitivity and resistance of human glioblastoma multiforme cell lines to erlotinib. Laboratory investigation[J]. J Neurosurg, 2009,111(2):211-218.

[15] CHEUNG H C,BAGGERLY K A,TSAVACHIDIS S,et al. Global analysis of aberrant pre-mRNA splicing in glioblastoma using exon expression arrays[J]. BMC Genomics,2008,9:216.

[16] LIU X,CHONG Y,TU Y,et al. CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways[J]. J Hematol Oncol,2016, 9(1):108.

[17] JIN Y,XIAO W,SONG T,et al. Expression and prognostic significance of p53 in glioma patients:A meta-analysis[J]. Neurochem Res,2016,41(7):1723-1731.

[18] CHOU T T,TROJANOWSKI J Q,LEE VM. Neurotrophin signal transduction in medulloblastoma[J]. J Neurosci Res, 1997, 49(5):522-527.

[19] WASHIYAMA K,MURAGAKI Y,RORKE L B,et al. Neurotrophin and neurotrophin receptor proteins in medullo-blastomas and other primitive neuroectodermal tumors of the pediatric central nervous system[J]. Am J Pathol,1996,148(3):929-940.

[20] LUKASHOVA-V ZANGEN I,KNEITZ S,MONORANU C M,et al. Ependymoma gene expression profiles associated with histological subtype,proliferation,and patient survival[J]. Acta Neuropathol,2007,113(3):325-337.

[21] CVEKL A,J R.,ZAVADIL J,BIRSHTEIN B K,et al. Analysis of transcripts from 17p13.3 in medulloblastoma suggests ROX/MNT as a potential tumour suppressor gene[J]. Eur J Cancer,2004, 40(16):2525-2532.

[22] CUPPENS T,TUYAERTS S,AMANT F. Potential therapeutic targets in uterine sarcomas[J]. Sarcoma,2015,2015:243298.

[23] KARLSSON J,VALIND A,GISSELSSON D. BCOR internal tandem duplication and YWHAE-NUTM2B/E fusion are mutually exclusive events in clear cell sarcoma of the kidney[J]. Genes Chrom Cancer,2016,55(2):120-123.

[24] JOCHMANOVA I,ZHUANG Z,PACAK K. Pheochro-mocytoma:Gasping for air[J]. Horm Cancer,2015, 6(5/6):191-205.

[25] CASCóN A,COMINO-MéNDEZ I,CURRáS-FREIXES M, et al. Whole-exome sequencing identifies MDH2 as a new familial paraganglioma gene[J]. J Natl Cancer Inst,2015. doi:10.1093/jnci/djv053.

[26] LIU Q,HARVEY C T,GENG H,et al. Malate dehydrogenase 2 confers docetaxel resistance via regulations of JNK signaling and oxidative metabolism[J]. Prostate,2013,73(10):1028-1037.

[27] LO Y W,LIN S T,CHANG S J,et al. Mitochondrial proteomics with siRNA knockdown to reveal ACAT1 and MDH2 in the development of doxorubicin-resistant uterine cancer[J]. J Cell Mol Med,2015,19(4):744-759.

[28] SCHULZ D M,BOLLNER C,THOMAS G,et al. Identification of differentially expressed proteins in triple-negative breast carcinomas using DIGE and mass spectrometry[J]. J Proteome Res,2009,8(7):3430-3438.

[29] KAUSHIK N K,KAUSHIK N,YOO K C,et al. Low doses of PEG-coated gold nanoparticles sensitize solid tumors to cold plasma by blocking the PI3K/AKT-driven signaling axis to suppress cellular transformation by inhibiting growth and EMT[J]. Biomaterials,2016,87:118-130.

[30] YAO C,LI P,SONG H,et al. CXCL12/CXCR4 axis upregulates twist to induce EMT in human glioblastoma[J]. Mol Neurobiol, 2016,53:3948.

[31] CHANG Y,LI L,ZHANG L,et al. Plexin-B1 indirectly affects glioma invasiveness and angiogenesis by regulating the RhoA/alphavbeta3 signaling pathway and SRPK1[J]. Tumour Biol,2016:11225-11236.

[32] NI W,FANG Y,TONG L,et al. Girdin regulates the migration and invasion of glioma cells via the PI3K-Akt signaling pathway[J]. Mol Med Rep,2015,12(4):5086-5092.

[33] MA Q,ZHANG Y,MENG R,et al. MAGI3 suppresses glioma cell proliferation via upregulation of PTEN expression[J]. Biomed Environ Sci,2015,28(7):502-509.

[34] DUZGUN Z,EROGLU Z,BIRAY A C. Role of mTOR in glioblastoma[J]. Gene,2016,575(2 Sup 1):187-190.

Copy number of gene and their expression as survival markers for glioma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	ZHENG Jiantao, YANG Yong, ZHOU Dong. Clinical significance of CX43 expression and immune cell infiltration in glioma: based on TCGA data analyses [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 250-254,261.
[2]	WAN Xin, HU Yue, ZHANG Ju, CHEN Yun, JIN Peipei. Human herpesvirus 6A subtype affects the expression of LncRNA MEG3,proliferation,apoptosis and EMT process in glioma cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(5): 352-358.
[3]	DONG Qiang, XIE Qiqi, HU Jianhong, WANG Maolin, YUAN Guoqiang, PAN Yawen. Bioinformatic analysis of expression and clinical significance of formyl peptide receptor 1 in gliomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(6): 457-462.
[4]	GAO Fei, WANG Yingbin. Experimental transcarotid artery chemotherapy on gliomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(1): 62-66.
[5]	HUANG Yongsheng, LIU Wenbin, HAN Fei, CUI Zhihong, AO Lin, CAO Jia, LIU Jinyi. MPDZ copy number variations, expression and prognostic value in liver cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(3): 161-165.
[6]	ZHANG Haiyan, LI Qingye, CHEN Shen, CHEN Wen, HE Zhini. Construction of an environmental pollution-responsive gene-specific pyrosequencing assay [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(2): 81-86.
[7]	ZHENG Jian, LAN Tao, LIU Wei, DENG Rongxia, LI Peimao, ZHANG Yanfang, LIU Jianjun. Differentially expressed miRNA profile in workers with trichloroethylene-induced medicamentosa-like dermatitis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2016, 28(6): 468-471.
[8]	YAO Yujiang, XIE Ni, LIU Litao, LI Zhonghang, WAN Lili, ZHU Ting. Screening of genetic markers associated with lymph node metastasis in colorectal cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2015, 27(5): 332-340,346.
[9]	HE Jie, WAN Jinghai, LI Xueji, QIAN Haipeng, MENG Xiaoli, HAO Jiajie, XU Xin, WANG Mingrong. TERT promoter mutation is a potential biomarker for predicting poor outcome in gliomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2015, 27(5): 361-365.
[10]	LI Xia-jun，YANG Miao，DONG Zi-cheng，LIU Ran，YIN Li-hong，PU Yue-pu. Association between LncRNA-UCA1 expression and the risk for esophageal carcinoma in Huaian [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2014, 26(6): 407-411.
[11]	HUANG Su-ying;HUANG Chang-ming;TIAN Jun;CHEN Hua. Expression characteristics of serum AFP, CEA and CA19-9 in patients with gastrointestinal malignant tumors [J]. , 2012, 24(5): 376-378.
[12]	GAO Fei1, YOU Tian2, LU Jing-yu3, WANG Yun-jie4. The Expression of CAGE Gene and Its Mechanism in Intracranial Tumors [J]. , 2007, 19(3): 239-242.
[13]	JIANG You-hong;SUI Cheng-guang;MENG Fan-dong;MA Ping;WANG Xiao-hua;DAI Xiao-chun. Correlation Analysis Between Expression of P21WAF1/CIP1，P16 Proteins and Human Gliomas [J]. , 2005, 17(5): 311-313.
[14]	ZHANG Qiao， ZHOU Fang， LI Shi-en， et al. Effects of Coal Tar Pitch on DNA Damage in Peripheral Blood Lymphocyte in Occupationally Exposed Workers [J]. , 2004, 16(6): 338-340.
[15]	MU Yong-gao, CHEN Zhong-ping, ZHANG Xiang-heng, et al. Preliminary Results of Immunotherapy Against Malignant Gliomas Using Autologous Tumor Cell Vaccine [J]. , 2004, 16(4): 208-210.